巨细胞病毒感染

Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013 Mar;(13 suppl 4):93-106.

• 全文
• 摘要

Aberg JA. Reconstitution of immunity against opportunistic infections in the era of potent antiretroviral therapy. AIDS Clin Rev. 2000-2001:115-38.

• 摘要

Yinon Y, Farine D, Yudin MH, et al; Fetal Medicine Committee, Society of Obstetricians and Gynaecologists of Canada. Cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2010 Apr;32(4):348-354.

• 全文
• 摘要

Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74.

• 全文
• 摘要

Kotton CN, Kumar D, Caliendo AM, et al; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 Jun;102(6):900-31.

• 摘要

Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007 Sep;7(9):2106-13.

• 摘要

Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-e188.

• 摘要

Kimberlin DW, Jester PM, Sánchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 5;372(10):933-43.

• 全文
• 摘要

Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in cematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377(25):2433-44.

• 全文
• 摘要

Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005 Feb;5(2):218-27.

• 全文
• 摘要

Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):1-10.

• 全文
• 摘要

1.  Eid AJ, Razonable RR. Valganciclovir for the treatment of cytomegalovirus retinitis in patients with AIDS. Expert Rev Ophthalmol. 2007;2:351-61.

2.  Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013 Mar;(13 suppl 4):93-106.

• 全文
• 摘要

3.  Razonable RR, Paya CV. Beta-herpesviruses in transplantation. Rev Med Microbiol. 2002;13:163-76.

4.  Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infection in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant. 2003 Apr;17(2):114-20.

• 摘要

5.  Hayward GS, Ambinder R, Ciufo D, et al. Structural organization of human herpesvirus DNA molecules. J Invest Dermatol. 1984 Jul;83(1 suppl):29s-41s.

• 摘要

6.  Ayre K, Warren BF, Jeffery K, et al. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009 Sep;3(3):141-8.

• 摘要

7.  Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008 Jul 23;300(4):413-22.

• 全文
• 摘要

8.  Michaels MG, Greenberg DP, Sabo DL, et al. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatric Infect Dis J. 2003 Jun;22(6):504-9.

• 摘要

9.  Lagasse N, Dhooge I, Govaert P, et al. Congenital CMV infections and hearing loss. Acta Otorhinolaryngology Belg. 2000;54(4):431-6.

• 摘要

10.  Revello M. Pathogenesis and prenatal diagnosis of congenital cytomegalovirus infection. J Clin Virol. 2004 Feb;29(2):71-83.

• 摘要

11.  Kenneson A, Cannon MJ. Review and meta-analysis of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007 Jul-Aug;17(4):253-76.

• 摘要

12.  Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis. 2007 May 15;44(10):1315-20.

• 摘要

13.  Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD4 and Toll-like receptor 2. J Virol. 2003 Apr;77(8):4588-96.

• 全文
• 摘要

14.  Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):71-5.

• 摘要

15.  Eid AJ, Razonable RR. Cytomegalovirus in solid organ transplantation: advances lead to challenges and opportunities. Curr Opin Organ Transplant. 2007;12:610-17.

16.  Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001 Dec 1;184(11):1461-4.

• 摘要

17.  Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004 Mar 15;103(6):2003-8.

• 摘要

18.  Tedesco-Silva H, Felipe C, Ferreira A, et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant. 2015 Oct;15(10):2655-64.

• 全文
• 摘要

19.  Aberg JA. Reconstitution of immunity against opportunistic infections in the era of potent antiretroviral therapy. AIDS Clin Rev. 2000-2001:115-38.

• 摘要

20.  Weng MT, Tung CC, Lee YS, et al. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. BMC Gastroenterol. 2017 Feb 13;17(1):28.

• 全文
• 摘要

21.  Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm. 2005 Apr 15;62(8 suppl 1):S7-13.

• 摘要

22.  Yinon Y, Farine D, Yudin MH, et al; Fetal Medicine Committee, Society of Obstetricians and Gynaecologists of Canada. Cytomegalovirus infection in pregnancy. J Obstet Gynaecol Can. 2010 Apr;32(4):348-354.

• 全文
• 摘要

23.  Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003 May 15;101(10):4195-200.

• 全文
• 摘要

24.  AIDSinfo, US Department of Health & Human Services. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. May 2018 [internet publication].

• 全文

25.  Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 Apr 15;34(8):1094-7.

• 全文
• 摘要

26.  Razonable RR, Åsberg A, Rollag H, et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis. 2013 Jun;56(11):1546-53.

• 全文
• 摘要

27.  Preiksaitis JK, Hayden RT, Tong Y, et al. Are we there yet? Impact of the first International Standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016 Sep 1;63(5):583-9.

• 摘要

28.  Eid AJ, Bakri SJ, Kijpittayarit S, et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis. 2008 Feb;10(1):13-8.

• 摘要

29.  Razonable RR, Paya CV, Smith TF. Role of the laboratory in the diagnosis and management of cytomegalovirus infection in hematopoietic and solid organ transplant recipients. J Clin Microbiol. 2002 Mar;40(3):746-52.

• 全文
• 摘要

30.  Wohl DA, Kendall MA, Andersen J, et al; A5030 Study Team. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009 May-Jun;10(3):143-52.

• 全文
• 摘要

31.  Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001 May 3;344(18):1366-71.

• 全文
• 摘要

32.  Donner C, Liesnard C, Brancart F, et al. Accuracy of amniotic fluid testing before 21 weeks' gestation in prenatal diagnosis of congenital cytomegalovirus infection. Prenat Diagn. 1994 Nov;14(11):1055-9.

• 摘要

33.  Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74.

• 全文
• 摘要

34.  Ljungman P, Boeckh M, Hirsch HH, et al; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017 Jan 1;64(1):87-91.

• 摘要

35.  Kotton CN, Kumar D, Caliendo AM, et al; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 Jun;102(6):900-31.

• 摘要

36.  Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007 Sep;7(9):2106-13.

• 摘要

37.  Muller M, Wandel S, Colebunders R, et al; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Apr;10(4):251-61.

• 摘要

38.  Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-e188.

• 摘要

39.  Kimberlin DW, Jester PM, Sánchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 5;372(10):933-43.

• 全文
• 摘要

40.  Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul;143(1):16-25.

• 摘要

41.  Oliver SE, Cloud GA, Sánchez PJ, et al; National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec;(46 suppl 4):S22-6.

• 摘要

42.  Leruez-Ville M, Ghout I, Bussières L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol. 2016 Oct;215(4):462.e1-462.e10.

• 全文
• 摘要

43.  Nigro G, Adler SP, La Torre R, et al; Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005 Sep 29;353(13):1350-62.

• 全文
• 摘要

44.  Revello MG, Lazzarotto T, Guerra B, et al; CHIP Study Group. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014 Apr 3;370(14):1316-26.

• 全文
• 摘要

45.  Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008 Jan-Feb;22(1):89-97.

• 摘要

46.  American Society of Transplantation, American Society of Transplant Surgeons. Cytomegalovirus. Am J Transplant. 2004;4(suppl 10):51-8.

• 全文

47.  Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993 Dec;168(6):1506-9.

• 摘要

48.  Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26;369(13):1227-36.

• 摘要

49.  Marty FM, Winston DJ, Chemaly RF, et al. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Oct 4 [Epub ahead of print].

• 全文
• 摘要

50.  Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014 Jan;27(1):77-86.

• 全文
• 摘要

51.  Chemaly RF, Ullmann AJ, Stoelben S, et al; AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 8;370(19):1781-9.

• 摘要

52.  Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in cematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377(25):2433-44.

• 全文
• 摘要

53.  Webel R, Hakki M, Prichard MN, et al. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol. 2014 May;88(9):4776-85.

• 全文
• 摘要

54.  Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19;360(12):1191-9.

• 全文
• 摘要

55.  Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 Apr 9;377(9773):1256-63.

• 全文
• 摘要

56.  Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr;12(4):290-9.

• 摘要

57.  Vincenti F, Budde K, Merville P, et al. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant. 2018 May 9 [Epub ahead of print].

• 摘要

58.  Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016 Feb;3(2):e87-98.

• 全文
• 摘要

59.  Scheinberg P, Melenhorst JJ, Brenchley JM, et al. The transfer of adaptive immunity to cytomegalovirus (CMV) during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood. 2009 Dec 3;114(24):5071-80.

• 摘要

60.  Snyder LD, Chan C, Kwon D, et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016 Jan 1;193(1):78-85.

• 摘要

61.  Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013 Mar;56(6):817-24.

• 全文
• 摘要

62.  Manuel O, Kralidis G, Mueller NJ, et al; Swiss Transplant Cohort Study. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013 Sep;13(9):2402-10.

• 全文
• 摘要

63.  Martin-Gandul C, Mueller NJ, Pascual M, et al. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015 Dec;15(12):3024-40

• 全文
• 摘要

64.  Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005 Feb;5(2):218-27.

• 全文
• 摘要

65.  Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010 May;10(5):1228-37.

• 摘要

66.  Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid organ transplants: a systematic review of randomized clinical trials. Lancet. 2005 Jun 18-24;365(9477):2105-15.

• 摘要

67.  Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005 Dec 20;143(12):870-80.

• 摘要

68.  Small LN, Lau J, Snydman DR. Preventing post-organ transplant cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis. 2006 Oct 1;43(7):869-80.

• 摘要

69.  Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004 Apr;4(4):611-20.

• 摘要

70.  Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;(2):CD003774.

• 全文
• 摘要

71.  US Public Health Service (USPHS); Infectious Diseases Society of America (IDSA); USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials. 2001 Nov-Dec;2(6):493-554.

• 摘要

72.  Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996 Jun 6;334(23):1491-7.

• 全文
• 摘要

73.  Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 1998 Feb 12;12(3):269-77.

• 摘要

74.  Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):1-10.

• 全文
• 摘要

75.  Strippoli GF, Hodson EM, Jones C, et al. Preemptive treatment of cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation. 2006 Jan 27;81(2):139-45.

• 摘要

76.  Owers DS, Webster AC, Strippoli GF, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;(2):CD005133.

• 全文
• 摘要